IceCure Medical
Caesarea, Haifa District, Israel · Biotechnology, Health Care, Manufacturing
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
Key facts
- Headquarters
- Caesarea, Haifa District, Israel
- Employees
- 64
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (ICCM)
- Website
- icecure-medical.com
- Company page
Recent activity at IceCure Medical
- : IceCure Medical Enters Exclusive Distribution Agreement with Scovas for ProSense® Cryoablation Systems in the Netherlands.
- : IceCure Medical Ltd. launches the ProSense™ system for interventional oncology in Brazil following FDA clearance.
- : IceCure Medical Ltd
- : IceCure Medical Ltd
- : IceCure Medical Promotes Shay Levav to Chief Operating Officer
- : IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America
IceCure Medical funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Venture | $16.5M |
| Mar 2026 | Seed | $4.0M |
Leadership
- Andrey Sayapin, Director of Engineering
- Ronen Tsimerman, CFO & COO
- Shay Levav, Chief Operating Officer
- Shad Good, VP of Sales-North America
- Shad Good, Executive Vice President of Sales
Verified email and direct lines for IceCure Medical’s decision-makers are on Fundz. See plans
Employee benefit plans
IceCure Medical files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
IceCure Medical in the news
- IceCure Medical Receives Regulatory Approval to Market ProSense® in China - Yahoo Finance (Sep 10, 2026)
- IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site - PR Newswire (Jul 27, 2026)
- IceCure consolidates shares 30-to-1 in bid to keep Nasdaq listing - stocktitan.net (Jun 02, 2026)
- IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation - PR Newswire (Aug 13, 2026)
- IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance (May 12, 2026)
- IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment - PR Newswire (Aug 06, 2026)
- What's Going On With IceCure Medical Stock On Friday? - Benzinga (Jun 26, 2026)
- When Will IceCure Medical Ltd (NASDAQ:ICCM) Turn A Profit? - Yahoo Finance (Jan 15, 2026)
Companies similar to IceCure Medical
- Andersen Sterilizers · Biotechnology, Health Care, Manufacturing, Medical, Medical Device, medical devices
- PROTEOR · Biotechnology, Health Care, Manufacturing, Medical, Medical Device, medical devices
- Ronovo Surgical · Biotechnology, Health Care, Manufacturing, Medical, Medical Device, medical devices
- Anteris Technologies · Biotechnology, Health Care, Manufacturing, Medical, Medical Device, medical devices
- InMode · Biotechnology, Health Care, Manufacturing, Medical, Medical Device, medical devices
About IceCure Medical: questions and answers
What does IceCure Medical do?
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
Where is IceCure Medical headquartered?
IceCure Medical is headquartered in Caesarea, Haifa District, Israel.
How many employees does IceCure Medical have?
IceCure Medical has about 64 employees.
Has IceCure Medical raised funding?
Yes. Fundz has recorded 2 funding events for IceCure Medical. The most recent, $16.5M, was in Jun 2026.
Who leads IceCure Medical?
Shad Good is an Executive Vice President of Sales at IceCure Medical.
What is the latest news on IceCure Medical?
On Aug 24, 2026, IceCure Medical Enters Exclusive Distribution Agreement with Scovas for ProSense® Cryoablation Systems in the Netherlands.
Is IceCure Medical a public company?
Yes. IceCure Medical is publicly traded under the ticker ICCM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy